Clinical and Genomic Landscape of <i>FGFR3</i> Alterations Across Different Stages of Urothelial Cancer.

ABSTRACT:

Background and objective

Our aim was to provide a comprehensive analysis of the prevalence of potentially targetable activating FGFR3 alterations and their impact on oncological outcomes across different urothelial carcinoma (UC) stages.

Methods

We retrospectively analyzed clinical data and FGFR3 results for 1509 formalin-fixed, paraffin-embedded tissue specimens. Actionable activating FGFR3 mutations were assessed using a well-established multiplex SNaPshot polymerase chain reaction approach. FGFR3 fusion testing was performed with a Qiagen Therascreen kit.

Key findings and limitations

In the study population of 1509 patients, 202 (13%) had stage pTa, 380 (25%) had stage pT1, 258 (17%) had localized muscle-invasive bladder cancer (MIBC), 5

SUBMITTER: Haas M 

PROVIDER: S-EPMC12162067 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature